CVKD vs. IVA, NVCT, DBVT, INZY, TARA, MGX, ELUT, ENTA, IGMS, and CABA
Should you be buying Cadrenal Therapeutics stock or one of its competitors? The main competitors of Cadrenal Therapeutics include Inventiva (IVA), Nuvectis Pharma (NVCT), DBV Technologies (DBVT), Inozyme Pharma (INZY), Protara Therapeutics (TARA), Metagenomi (MGX), Elutia (ELUT), Enanta Pharmaceuticals (ENTA), IGM Biosciences (IGMS), and Cabaletta Bio (CABA). These companies are all part of the "pharmaceutical products" industry.
Cadrenal Therapeutics vs.
Cadrenal Therapeutics (NASDAQ:CVKD) and Inventiva (NASDAQ:IVA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership and profitability.
In the previous week, Inventiva had 1 more articles in the media than Cadrenal Therapeutics. MarketBeat recorded 1 mentions for Inventiva and 0 mentions for Cadrenal Therapeutics. Inventiva's average media sentiment score of 0.75 beat Cadrenal Therapeutics' score of 0.00 indicating that Inventiva is being referred to more favorably in the news media.
Inventiva received 14 more outperform votes than Cadrenal Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Cadrenal Therapeutics an outperform vote while only 80.00% of users gave Inventiva an outperform vote.
7.9% of Cadrenal Therapeutics shares are owned by institutional investors. Comparatively, 19.1% of Inventiva shares are owned by institutional investors. 48.6% of Cadrenal Therapeutics shares are owned by insiders. Comparatively, 32.0% of Inventiva shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Inventiva's return on equity of 0.00% beat Cadrenal Therapeutics' return on equity.
Cadrenal Therapeutics presently has a consensus target price of $32.00, suggesting a potential upside of 83.91%. Inventiva has a consensus target price of $13.25, suggesting a potential upside of 513.43%. Given Inventiva's higher possible upside, analysts plainly believe Inventiva is more favorable than Cadrenal Therapeutics.
Cadrenal Therapeutics has higher earnings, but lower revenue than Inventiva.
Cadrenal Therapeutics has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Inventiva has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500.
Summary
Inventiva beats Cadrenal Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Cadrenal Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CVKD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cadrenal Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CVKD) was last updated on 1/21/2025 by MarketBeat.com Staff
